Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904252 | 0.91 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL4603071 | 0.91 | CNR1 (0.57) | CNR1NPC1RAB9AL3MBTL1PKM | |
| 4-Imidazolecarboxylic Acid SCHEMBL4617313 | 0.91 | CNR1 (0.48) | CNR1NPC1RAB9AL3MBTL1PKM | |
| SCHEMBL4617309 | 0.89 | CNR1 (0.47) | CNR1NPC1RAB9AL3MBTL1PKM | |
| SCHEMBL4616359 | 0.88 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL4905590 | 0.86 | CNR1 (0.60) | CNR1NPC1RAB9AL3MBTL1PKM | |
| SCHEMBL3093294 | 0.82 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL4617465 | 0.79 | CNR1 (0.58) | CNR1 | |
| SCHEMBL3080647 | 0.77 | CNR1 (0.74) | CNR1NPC1RAB9AL3MBTL1CNR2 | |
| SCHEMBL4618787 | 0.76 | CNR1 (0.65) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | CNR2, CNR1, FAAH | CNR1 2/4885NPC1 658/4885RAB9A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.